Business
Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
CytoSorb now immediately commercially available throughout North America for use in COVID-19 patients, and in a total of 67 countries worldwide MONMOUTH
About this update from Cytosorbents Corporation
[{"type":"text","content":"CytoSorb now immediately commercially available throughout North America for use in COVID-19 patients, and in a total of 67 countries worldwide\n\n\nMONMOUTH JUNCTION, N.J., Jan. 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces that Health Canada has granted Medical Device Authorization for the importation, sale, and emergency use of CytoSorb in hospitalized COVID-19 patients under Interim Order (IO) ID# 316575. CytoSorbents will collaborate with ebbtides medical, a specialty distributor of medical products throughout Canada, to ensure rapid and widespread availability of the therapy.\n\n \n \n \n \n \n \n\n \nHealth Canada Authorization of CytoSorb for COVID-19 expands reach to all North America and 67 countries globallyMr. Steve Tymchuk, President and CEO of ebbtides medical stated, \"ebbtides medical is a well-established company located in Vancouver, with over 15 years of experience in the medical/surgical industry providing excellent solutions to the healthcare market, specializing in extracorporeal life support and cardiac surgery. We are excited to work with CytoSorbents to make CytoSorb immediately available during the COVID-19 crisis in Canada under Health Canada's COVID-19 Medical Device Authorization for Importation and Sale.\"\nMr. Vincent Capponi, President and Chief Operating Officer of CytoSorbents stated, \"We have worked closely with Health Canada and our new Canadian distributor, ebbtides medical, to achieve this special COVID-19 authorization. We are pleased to note that CytoSorb is now approved throughout North America for use in COVID-19 patients, and now commercially available in 67 countries worldwide. Cases of COVID-19 have been steadily rising in Canada, with approximately 600,000 confirmed cases already. Last month marked our first shipments of CytoSorb into Canada and we plan to work closely with ebbtides medical to deploy CytoSorb in hospitals throughout Canada to help as many patients as possible, particularly as most of the world waits for the COVID-19 vaccine. We believe the broad usage of CytoSorb, and multiple approvals and COVID-19 authorizations around the world speak to the value ...